Biological Therapy for Pustular Psoriasis: a Systematic Review

Overview

Journal Int J Dermatol

Specialty Dermatology

Date 2019 Oct 16

PMID 31612467

Citations 5

Authors

Leyre A Falto-Aizpurua

Rafael F Martin-Garcia

Osward Y Carrasquillo

Oscar W Nevares-Pomales

Xavier Sanchez-Flores

Deyson Lorenzo-Rios

Affiliations

Soon will be listed here.

Abstract

Background: The anecdotic evidence of the benefits from biologic agents for psoriasis is extensive. However, data on the efficacy of biologic agents for pustular psoriasis are limited.

Methods: To update the data on the efficacy and safety of biologic agents for the management of pustular psoriasis. A systematic review of published data regarding biologic therapies on PubMED database, used in the management of pustular psoriasis from 2012 was undertaken.

Results: A total of 209 articles were identified, and 43 articles were selected for inclusion. TNF-α inhibitors were used in 205 patients, and 86 patients received ustekinumab, secukinumab, brodalumab, ixekizumab and IL-1 inhibitors. Overall response was favorable for most modalities. No serious adverse events were reported. Inconsistent measures of treatment response and study variability limited the overall evaluation of data.

Conclusions: Infliximab and ustekinumab have the most evidence of efficacy and safety for the treatment of pustular psoriasis. Recent evidence supports the use of IL-17 antagonists. Prospective controlled and comparative trials are needed to further explore the efficacy and safety of biologic agents in order to establish objective recommendations for the management of this challenging condition.

Citing Articles

Updated genetic background of generalized pustular psoriasis as an autoinflammatory keratinization disease.

Akiyama M J Dermatol. 2024; 52(3):400-407.

PMID: 39698752 PMC: 11883853. DOI: 10.1111/1346-8138.17585.

Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report.

Yang X, Wang J, Wang H, Kong M, Chen Q Clin Cosmet Investig Dermatol. 2022; 15:2541-2546.

PMID: 36466946 PMC: 9709846. DOI: 10.2147/CCID.S391463.

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.

Okubo Y, Umezawa Y, Sakurai S, Hoshii N, Nakagawa H Dermatol Ther (Heidelb). 2022; 12(6):1397-1415.

PMID: 35622315 PMC: 9209588. DOI: 10.1007/s13555-022-00741-x.

Pustular Psoriasis: From Pathophysiology to Treatment.

Genovese G, Moltrasio C, Cassano N, Maronese C, Vena G, Marzano A Biomedicines. 2021; 9(12).

PMID: 34944562 PMC: 8698272. DOI: 10.3390/biomedicines9121746.

HLA genotypes and cold medicine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis.

Tangamornsuksan W, Chanprasert S, Nadee P, Rungruang S, Meesilsat N, Ueta M Sci Rep. 2020; 10(1):10589.

PMID: 32601360 PMC: 7324363. DOI: 10.1038/s41598-020-67610-5.